|
[1] LUDWIG J,VIGGIANO TR,MCGILL DB,et al. Nonalcoholic steatohepatitis:Mayo Clinic experiences with a hitherto unnamed disease[J]. Mayo Clin Proc,1980,55(7):434-438.
|
|
[2] YOUNOSSI Z,ANSTEE QM,MARIETTI M,et al. Global burden of NAFLD and NASH:Trends,predictions,risk factors and prevention[J]. Nat Rev Gastroenterol Hepatol,2018,15(1):11-20.
|
|
[3] BUZZETTI E,PINZANI M,TSOCHATZIS EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease(NAFLD)[J]. Metabolism,2016,65(8):1038-1048.
|
|
[4] SKOIEN R,RICHARDSON MM,JONSSON JR,et al. Heterogeneity of fibrosis patterns in non-alcoholic fatty liver disease supports the presence of multiple fibrogenic pathways[J].Liver Int,2013,33(4):624-632.
|
|
[5] FRIEDMAN SL,NEUSCHWANDER-TETRI BA,RINELLA M,et al. Mechanisms of NAFLD development and therapeutic strategies[J]. Nat Med,2018,24(7):908-922.
|
|
[6] MCPHERSON S,HARDY T,DUFOUR JF,et al. Age as a Confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis[J]. Am J Gastroenterol,2017,112(5):740-751.
|
|
[7] de SILVA S,LI W,KEMOS P,et al. Non-invasive markers of liver fibrosis in fatty liver disease are unreliable in people of South Asian descent[J]. Frontline Gastroenterol,2018,9(2):115-121.
|
|
[8] DREW L. Development pipeline review 2018[J]. Nature,2017,551(2):s86-s89.
|
|
[9] FRIEDMAN SL,NEUSCHWANDER-TETRI BA,RINELLA M,et al. Mechanisms of NAFLD development and therapeutic strategies[J]. Nat Med,2018,24(7):908-922.
|
|
[10] YKI-JARVINEN H,LUUKKONEN PK. Heterogeneity of non-alcoholic fatty liver disease[J]. Liver Int,2015,35(12):2498-2500.
|
|
[11] LONARDO A,BALLESTRI S,TARGHER G．“Not all forms of NAFLD were created equal”. Do metabolic syndrome-related NAFLD and PNPLA3-related NAFLD exert a variable impact on the risk of early carotid atherosclerosis?[J]. Atherosclerosis,2017,257:253-255.
|
|
[12] ADAMS LA,LYMP JF,ST SAUVER J,et al. The natural history of nonalcoholic fatty liver disease:A population-based cohort study[J]. Gastroenterology,2005,129(1):113-121.
|
|
[13] ANGULO P,KLEINER DE,DAM-LARSEN S,et al. Liver fibrosis,but no other histologic features,is associated with longterm outcomes of patients with nonalcoholic fatty liver disease[J]. Gastroenterology,2015,149(2):389-397. e10.
|
|
[14] VILAR-GOMEZ E,CALZADILLA-BERTOT L,WAI-SUN WONG V,et al. Fibrosis severity as a determinant of causespecific mortality in patients with advanced nonalcoholic fatty liver disease:A multi-national cohort study[J]. Gastroenterology,2018,155(2):443-457. e17.
|
|
[15] SINGH S,ALLEN AM,WANG Z,et al. Fibrosis progression in nonalcoholic fatty liver versus nonalcoholic steatohepatitis:A systematic review and meta-analysis of paired-biopsy studies[J]. Clin Gastroenterol Hepatol,2015,13(4):643-654.
|
|
[16] VILAR-GOMEZ E,MARTINEZ-PEREZ Y,CALZADILLA-BERTOT L,et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis[J]. Gastroenterology,2015,149(2):367-378. e5; quiz e14-15.
|
|
[17] LOOMBA R,ABRAHAM M,UNALP A,et al. Association between diabetes,family history of diabetes,and risk of nonalcoholic steatohepatitis and fibrosis[J]. Hepatology,2012,56(3):943-951.
|
|
[18] PELUSI S,CESPIATI A,RAMETTA R,et al. Prevalence and risk factors of significant fibrosis in patients with nonalcoholic fatty liver without steatohepatitis[J]. Clin Gastroenterol Hepatol,2019,17(11):2310-2319. e6.
|
|
[19] FRITH J,DAY CP,HENDERSON E,et al. Non-alcoholic fatty liver disease in older people[J]. Gerontology,2009,55(6):607-613.
|
|
[20] DONATI B,VALENTI L. Telomeres,NAFLD and chronic liver disease[J]. Int J Mol Sci,2016,17(3):383.
|
|
[21] PAPATHEODORIDI AM,CHRYSAVGIS L,KOUTSILIERIS M,et al. The role of senescence in the development of nonalcoholic fatty liver disease and progression to nonalcoholic steatohepatitis[J]. Hepatology,2020,71(1):363-374.
|
|
[22] KUK JL,SAUNDERS TJ,DAVIDSON LE,et al. Age-related changes in total and regional fat distribution[J]. Ageing Res Rev,2009,8(4):339-348.
|
|
[23] CHURILLA JR,FITZHUGH EC,THOMPSON DL. The metabolic syndrome:How definition impacts the prevalence and risk in U. S. adults:1999-2004 NHANES[J]. Metab Syndr Relat Disord,2007,5(4):331-342.
|
|
[24] LEE YH,JUNG KS,KIM SU,et al. Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance:Nationwide surveys(KNHANES 2008-2011)[J]. J Hepatol,2015,63(2):486-493.
|
|
[25] LEE YH,KIM SU,SONG K,et al. Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease:Nationwide surveys(KNHANES 2008-2011)[J]. Hepatology,2016,63(3):776-786.
|
|
[26] LONARDO A,NASCIMBENI F,BALLESTRI S,et al. Sex differences in nonalcoholic fatty liver disease:State of the art and identification of research gaps[J]. Hepatology,2019,70(4):1457-1469.
|
|
[27] ANDERSON EL,HOWE LD,JONES HE,et al. The prevalence of non-alcoholic fatty liver disease in children and adolescents:A systematic review and Meta-analysis[J]. PLo S One,2015,10(10):e0140908.
|
|
[28] YANG JD,SUZUKI A. The influence of menopause on the development of hepatic fibrosis in nonobese women with nonalcoholic fatty liver disease reply[J]. Hepatology,2014,60(5):1792-1793.
|
|
[29] MARIN V,ROSSO N,DAL BEN M,et al. An animal model for the juvenile non-alcoholic fatty liver disease and non-alcoholic steatohepatitis[J]. PLo S One,2016,11(7):e0158817.
|
|
[30] RICH NE,OJI S,MUFTI AR,et al. Racial and ethnic disparities in nonalcoholic fatty liver disease prevalence,severity,and outcomes in the United States:A systematic review and Meta-analysis[J]. Clin Gastroenterol Hepatol,2018,16(2):198-210. e2.
|
|
[31] ZHOU F,ZHOU J,WANG W,et al. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018:A systematic review and Meta-analysis[J]. Hepatology,2019,70(4):1119-1133.
|
|
[32] TABIBIAN JH,LAZO M,DURAZO FA,et al. Nonalcoholic fatty liver disease across ethno-racial groups:Do Asian-American adults represent a new at-risk population?[J]. J Gastroenterol Hepatol,2011,26(3):501-509.
|
|
[33] VANWAGNER LB,NING H,ALLEN NB,et al. Alcohol use and cardiovascular disease risk in patients with nonalcoholic fatty liver disease[J]. Gastroenterology,2017,153(5):1260-1272. e3.
|
|
[34] CHANG Y,CHO YK,KIM Y,et al. Nonheavy drinking and worsening of noninvasive fibrosis markers in nonalcoholic fatty liver disease:A Cohort study[J]. Hepatology,2019,69(1):64-75.
|
|
[35] CAUSSY C,LOOMBA R. Gut microbiome,microbial metabolites and the development of NAFLD[J]. Nat Rev Gastroenterol Hepatol,2018,15(12):719-720.
|
|
[36] ARAB JP,KARPEN SJ,DAWSON PA,et al. Bile acids and nonalcoholic fatty liver disease:Molecular insights and therapeutic perspectives[J]. Hepatology,2017,65(1):350-362.
|
|
[37] DING C,CHAN Z,MAGKOS F. Lean,but not healthy:the'metabolically obese,normal-weight’phenotype[J]. Curr Opin Clin Nutr Metab Care,2016,19(6):408-417.
|
|
[38] HAGSTROM H,NASR P,EKSTEDT M,et al. Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease:A long-term follow-up study[J]. Hepatol Commun,2018,2(1):48-57.
|
|
[39] LEUNG JC,LOONG TC,WEI JL,et al. Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients[J]. Hepatology,2017,65(1):54-64.
|
|
[40] FRACANZANI AL,PETTA S,LOMBARDI R,et al. Liver and cardiovascular damage in patients with lean nonalcoholic fatty liver disease,and association with visceral obesity[J]. Clin Gastroenterol Hepatol,2017,15(10):1604-1611. e1.
|
|
[41] CHEN F,ESMAILI S,ROGERS GB,et al. Lean NAFLD:A distinct entity shaped by differential metabolic adaptation[J].Hepatology,2020,71(4):1213-1227.
|
|
[42] LOOMBA R,SCHORK N,CHEN CH,et al. Heritability of hepatic fibrosis and steatosis based on a prospective twin study[J]. Gastroenterology,2015,149(7):1784-1793.
|
|
[43] STRUBEN VM,HESPENHEIDE EE,CALDWELL SH. Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds[J]. Am J Med,2000,108(1):9-13.
|
|
[44] CAUSSY C,SONI M,CUI J,et al. Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis[J]. J Clin Invest,2017,127(7):2697-2704.
|
|
[45] LIU CH,AMPUERO J,GIL-GOMEZ A,et al. miRNAs in patients with non-alcoholic fatty liver disease:A systematic review and meta-analysis[J]. J Hepatol,2018,69(6):1335-1348.
|
|
[46] ATANASOVSKA B,RENSEN SS,VAN DER SIJDE MR,et al.A liver-specific long noncoding RNA with a role in cell viability is elevated in human nonalcoholic steatohepatitis[J]. Hepatology,2017,66(3):794-808.
|
|
[47] ZHAO XY,XIONG X,LIU T,et al. Long noncoding RNA licensing of obesity-linked hepatic lipogenesis and NAFLD pathogenesis[J]. Nat Commun,2018,9(1):2986.
|
|
[48] SOOKOIAN S,FLICHMAN D,GARAYCOECHEA ME,et al.Metastasis-associated lung adenocarcinoma transcript 1 as a common molecular driver in the pathogenesis of nonalcoholic steatohepatitis and chronic immune-mediated liver damage[J]. Hepatol Commun,2018,2(6):654-665.
|
|
[49] HARDY T,ZEYBEL M,DAY CP,et al. Plasma DNA methylation:A potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease[J]. Gut,2017,66(7):1321-1328.
|
|
[50] ESLAM M,SANYAL AJ,GEORGE J,et al. MAFLD:A consensus-driven proposed nomenclature for metabolic associated fatty liver disease[J]. Gastroenterology,2020,158(7):1999-2014. e1.
|
|
[51] GU J,LIU S,DU S,et al. Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease:A meta-analysis[J]. Eur Radiol,2019,29(7):3564-3573.
|
DownLoad: